Calais G, Reynaud-Bougnoux A, Garand G, Beutter P, Le Floch O
Department of Oncology and Radiotherapy, University Hospital of Tours, France.
Br J Radiol. 1990 May;63(749):340-5. doi: 10.1259/0007-1285-63-749-340.
Induction chemotherapy (CT) has demonstrated overall response rates of 80% for oropharynx carcinomas, but no overall survival benefit has been reported. In order to determine the value of induction CT for such patients, we conducted a retrospective study: 121 patients were treated with CT and radiotherapy (RT) (Group 1). This group was compared with a historical group of 84 patients treated by RT alone (Group 2). The CT used was Cisplatinum associated with Bleomycin and Vincristin or Vindesin and with 5 Fluoro-uracil. An objective response to CT was observed for 41% of patients. The 5 year actuarial survival rate was 19% for Group 1 and 24% for Group 2. Patterns of failure were identical in the two groups. The only difference observed was for patients with N3 nodes (26% of 5 year survival rate in Group 1 versus 9% in Group 2) (p = 0.05). The results did not depend on the histological differentiation, the tumour site or the type of CT. We conclude that this retrospective study failed to demonstrate an advantage for induction CT in oropharynx carcinoma except for patients with N3 nodes.
诱导化疗(CT)已显示口咽癌的总体缓解率为80%,但尚未有总体生存获益的报道。为了确定诱导CT对此类患者的价值,我们进行了一项回顾性研究:121例患者接受了CT和放疗(RT)(第1组)。该组与84例仅接受RT治疗的历史患者组(第2组)进行比较。所用的CT为顺铂联合博来霉素和长春新碱或长春地辛以及5-氟尿嘧啶。41%的患者对CT有客观反应。第1组的5年精算生存率为19%,第2组为24%。两组的失败模式相同。观察到的唯一差异在于N3淋巴结转移患者(第1组5年生存率为26%,第2组为9%)(p = 0.05)。结果不取决于组织学分化、肿瘤部位或CT类型。我们得出结论,这项回顾性研究未能证明诱导CT对口咽癌有优势,N3淋巴结转移患者除外。